Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 9/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 7/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.90 |
| ▸ | MEN1 | O00255 | 2/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.90 |
| ▸ | POLB | P06746 | 1/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.90 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nornicotine SCHEMBL13090363 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Nornicotine SCHEMBL29571520 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Nornicotine SCHEMBL158145 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Nornicotine SCHEMBL158146 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Nornicotine SCHEMBL29362147 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Nornicotine SCHEMBL30866559 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Nornicotine SCHEMBL932560 | 0.98 | CHRNB2 (0.96) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL117530 | 0.95 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL30835558 | 0.95 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Anabasine SCHEMBL29634446 | 0.95 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116354841-B | Method for synthesizing formamide by catalyzing lower amine and carbon dioxide by polymer-based catalyst | 中国科学院兰州化学物理研究所 | 2024-06-14 | — | — | CN | claimed |
| CN-116354841-A | Method for synthesizing formamide by catalyzing lower amine and carbon dioxide by polymer-based catalyst | 中国科学院兰州化学物理研究所 | 2023-06-30 | — | — | CN | claimed |
| EP-1284976-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2003-02-26 | — | — | EP | claimed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | claimed |
| EP-4638433-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240279215-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED | 2024-08-22 | — | — | US | disclosed |
| WO-2024137981-A1 | NAMPT MODULATORS | CYTOKINETICS, INCORPORATED (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-116354841-B | Method for synthesizing formamide by catalyzing lower amine and carbon dioxide by polymer-based catalyst | 中国科学院兰州化学物理研究所 | 2024-06-14 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230301341-A1 | COMPOSITIONS AND METHODS FOR SUBLINGUAL DELIVERY OF NICOTINE | Poviva Corp. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230301341-A1 | COMPOSITIONS AND METHODS FOR SUBLINGUAL DELIVERY OF NICOTINE | Poviva Corp. (US) | 2023-09-28 | — | — | US | disclosed |
| US-11700875-B1 | Compositions and methods for sublingual delivery of nicotine | Poviva Corp. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2011111875-A1 | N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | WO | disclosed |
| US-20110112130-A1 | Opioid-Nornicotine Codrugs Combinations for Pain Management | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100216847-A1 | NORNICOTINE FOR THE TREATMENT OF PAIN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216847-A1 | NORNICOTINE FOR THE TREATMENT OF PAIN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100048605-A1 | SYNERGISTIC EFFECTS OF COMBINATIONS OF NORNICOTINE AND OPIOIDS FOR THE TREATMENT OF PAIN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048605-A1 | SYNERGISTIC EFFECTS OF COMBINATIONS OF NORNICOTINE AND OPIOIDS FOR THE TREATMENT OF PAIN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2009121018-A2 | OPIOID-NORNICOTINE CODRUGS FOR PAIN MANAGEMENT | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2008063556-A2 | NORNICOTINE FOR THE TREATMENT OF PAIN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048605-A1 | SYNERGISTIC EFFECTS OF COMBINATIONS OF NORNICOTINE AND OPIOIDS FOR THE TREATMENT OF PAIN | OPRL1, OPRM1, OPRD1 | CHRNB2 79/4885CHRNA4 208/4885CHRNA7 151/4885 |
| US-20100216847-A1 | NORNICOTINE FOR THE TREATMENT OF PAIN | OPRL1, NAPRT, OPRM1 | CHRNB2 106/4885CHRNA4 303/4885CHRNA7 183/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | CHRNB2 2750/4885CHRNA4 2524/4885CHRNA7 2813/4885 |
| US-20240279215-A1 | NAMPT MODULATORS | NAMPT, SIRT1, NNT | CHRNB2 2854/4885CHRNA4 2804/4885CHRNA7 2605/4885 |
| US-20110112130-A1 | Opioid-Nornicotine Codrugs Combinations for Pain Management | OPRM1, OPRL1, OPRK1 | CHRNB2 91/4885CHRNA4 51/4885CHRNA7 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.